Amplify Seymour Cannabis ETF (CNBS) Falls -13% as Regulatory Pause Weighs on Sector

Key Takeaways

• CNBS declined roughly 13% over the last 30 days, from about $26.13 to $22.82 per share, as US cannabis equities sold off sharply.
• Over the last quarter the fund is down about 9%, having rallied toward $30 in late September before the October reversal.
• The primary catalyst was a pause in the DEA's federal marijuana rescheduling proceeding, which delayed a key policy-driven investment theme.
• Top equity exposures such as Trulieve Cannabis, Curaleaf Holdings, and Green Thumb Industries were among the heaviest decliners.
• Regulatory timing, rather than underlying operating results, has driven recent ETF performance and sector sentiment.
• CNBS is actively managed and uses total return swaps backed by Treasury bills to access multi-state operators not listed on major US exchanges.
• For additional context, review CNBS Price Targets and Forecast pages to monitor forward-looking analyst views and projected signals.
• Explore Trending AI Robots to see how automated strategies are positioning across the market.

CNBS ETF Overview and Portfolio Exposure

The Amplify Seymour Cannabis ETF (CNBS) is an actively managed fund that seeks capital appreciation by investing at least 80% of its net assets in US companies deriving 50% or more of their revenue from the cannabis and hemp ecosystem. It also uses derivatives, primarily total return swaps, to gain economic exposure to the sector. The fund is non-diversified, launched in 2019, and carries a net expense ratio of 0.76% after fee waivers, with approximately $64 million in assets under management (AUM) and roughly 33 holdings.

Because many of the largest US cannabis operators do not trade on major domestic exchanges, CNBS holds substantial positions in Treasury bills that serve as collateral for swaps providing exposure to multi-state operators (MSOs) — companies licensed to cultivate and sell cannabis across multiple states. Its market allocation is dominated by MSOs at about 85%, followed by real estate, cultivation and retail, and agricultural technology. Key equity exposures include Trulieve Cannabis (TRLV), Curaleaf Holdings, and Green Thumb Industries, alongside ancillary names such as Innovative Industrial Properties (IIPR) and GrowGeneration (GRWG). This concentrated, swap-driven structure means the fund moves closely with a handful of MSOs, amplifying sector-wide swings in both directions. I also checked this using Tickeron’s AI Screener to see how the holdings compare to others in the industry.

CNBS Price Performance Over the Last 30 Days and Quarter

Over the last 30 days, CNBS fell approximately 12.7%, from a closing level near $26.13 to about $22.82. The decline was not gradual: the fund had climbed to a recent peak around $30.78 in late September before a sharp, policy-driven selloff in the final days of September carried into October. The move was trend-reversing rather than range-bound, with most of the damage concentrated around a single regulatory event and subsequent headline-driven pressure.

The quarterly picture is somewhat different. From roughly $25.06 three months ago to about $22.82 today, CNBS is down approximately 8.9%. That gap between the 30-day and quarterly figures reflects a mid-quarter rally that was fully reversed, underscoring how quickly sentiment can shift in a sector whose equity valuations remain tightly linked to federal policy expectations.

What Drove CNBS Price in the Last 30 Days

The dominant driver was regulatory. In late September, a Drug Enforcement Administration (DEA) administrative law judge paused the hearing on rescheduling marijuana from Schedule I to Schedule III, after opponents invoked a Government Accountability Office (GAO) report citing procedural gaps in the federal review process. Because rescheduling is the central catalyst for US cannabis MSOs — largely for relief from Section 280E tax restrictions and broader institutional access — the delay triggered a broad selloff across the sector.

Leading holdings bore the brunt. Trulieve Cannabis, Curaleaf Holdings, and Green Thumb Industries each posted double-digit percentage declines around the announcement, with smaller swap exposures such as Verano Holdings, Cresco Labs, and Glass House Brands falling in tandem. This concentration meant CNBS tracked those losses closely. In April, the federal government had already rescheduled state-licensed medical cannabis to Schedule III, providing some tax relief, but the October pause pushed back expectations for a broader adult-use reclassification into 2027, weakening near-term sentiment.

What Drove CNBS Performance Over the Last Quarter

The three-month trend has been shaped by an earlier risk-on phase followed by a sharp de-rating. Through the summer, US cannabis equities rallied on optimism around federal reform and improving operator fundamentals, lifting CNBS toward its late-September high. Trulieve's uplisting to the NYSE and its September inclusion in a broad US market index also improved perceived institutional accessibility for the space.

That momentum reversed as the rescheduling timeline extended. The procedural pause reframed the sector from an imminent-catalyst story back to a longer-dated regulatory call, prompting investors to reassess valuations that had partly priced in faster reform. The result was a quarter that began and ended lower even as mid-period strength briefly suggested a breakout, leaving CNBS down roughly 9% over the period.

CNBS ETF Outlook: What Investors Should Watch Next

Going forward, the rescheduling timeline remains the central variable. Investors should monitor DEA procedural developments, including briefing deadlines and any decisions on reopening the hearing, as well as the broader path from Schedule I toward Schedule III and the potential extension of Section 280E relief to adult-use operators. State-level reforms and new market openings, such as adult-use programs in states including Virginia and Texas, could influence individual MSO earnings.

Company fundamentals also matter: revenue growth, free cash flow, balance-sheet deleveraging, and consolidation activity across major holdings will shape relative performance independent of policy headlines. Broader macro conditions, including interest-rate expectations and risk appetite for small- and mid-cap growth equities, remain relevant given the sector's high-beta profile. Finally, institutional capital flows and potential M&A activity — including disputes among operators — could drive volatility. These themes, rather than any single price level, are likely to define CNBS's trajectory in the months ahead. From what I see, this is important because the fund's performance remains closely tied to these policy milestones.

AI Screener

I often turn to Tickeron's AI Screener when analyzing policy-sensitive sectors like cannabis. The platform lets me scan for technical signals, fundamentals, and industry trends in one place, helping me spot how CNBS compares to peers without sifting through data manually. It has become a regular part of my research workflow for identifying shifting themes and relative strength.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume